Edwards Lifesciences Corp. will issue $600 million of 4.300% senior unsecured notes due 2028.
The Irvine, Calif.-based medical device maker said it expects net proceeds of $594.7 million from the offering.
Merrill Lynch Pierce Fenner & Smith Inc., J.P. Morgan Securities LLC, Deutsche Bank Securities Inc., HSBC Securities (USA) Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities LLC are serving as joint book-running managers.
